Hints and tips:
Related Special Reports
...Rival biotech group Intellia Therapeutics plans to seek US approval for its own trial in the second half of 2020....
...Acorda Therapeutics increased the price of its multiple sclerosis drug Ampyra by 9.5 per cent to $53.85 per tablet, taking a bottle of 60 to more than $3,000....
...AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal...
...According to Ben Shepherd, director of therapeutics at Organovo, the challenges ahead are about increasing the size of the tissue that can be grown....
...Shares in Celldex Therapeutics fell 53.7 per cent to $3.79, after the biopharmaceutical company said it would discontinue a late-stage study of its brain cancer treatment, Rintega, after an independent interim...
...“The ideas bounced around for years but there were no believers,” recalls Tom Davis, who was director of clinical science at Medarex and is now at Celldex, another biotech company....
International Edition